Reply  by Mwipatayi, B. Patrice
would argue that such a life expectancy is certainly long enough
not to simply disregard the radiocephalic fistula.
Andy Robert Weale, MRCS
Surgery, Southmead Hospital
Bristol, Avon, United Kingdom
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Regarding “Stenting for femoropopliteal lesions”
We have read with interest the article by Mwipatayi et al1 on
the contemporary topic of femoropopliteal stenting. Unfortu-
nately, the authors’ conclusion that stent placement for treatment
of femoropopliteal disease does not increase patency at 1 year
compared with balloon angioplasty alone is flawed by several
unacceptable limitations of this meta-analysis.
Clinical heterogeneity of the included studies is the most
relevant drawback: First, different types of stents (balloon-
expanding stainless steel stents, self-expanding Elgiloy stents, self-
expanding Nitinol stents, and polytetrafluoroethylene-covered stent
grafts) were included in the analysis. Each of these devices has
fundamentally differential characteristics, indications, and out-
comes, and therefore cannot be summarized as one category.2
Second, seven prospective randomized studies were mixed with
the results of a retrospective and purely observational study. Par-
ticularly, the latter study was of extremely poor quality without
standardized follow-up intervals (follow-up ranged from 1 to 72
months). Third, clinical characteristics of patients treated within
the studies were highly variable: Balloon-expanding stents can be
used for only very short lesions (spot stenting), whereas stent grafts
and self-expanding stents are implanted for longer lesions. Because
of this selection bias, it is impossible to assess whether stents may
have beneficial effects in certain predefined subgroups (eg, patients
with long lesions or total occlusions). Fourth, treatment strategies
within the different trials were not consistent: six randomized
studies including short lesions compared primary stenting vs bal-
loon angioplasty alone. In contrast, one study that also included
longer lesions compared primary stenting vs balloon angioplasty
with optional secondary stenting.3
In Table 1 restenosis and patency rates of the ABSOLUTE
trial3 at 12 months are mixed up (the table reports 63% patency
rate, which should read 37%). This overestimation may have sig-
nificantly influenced the pooled risk estimates.
Addressing the issue of stent fractures, six of the eight studies
did not systematically assess stent fractures; therefore, this end
point should not be reported.
Finally, a cut off for including studies published later than the
year 2000 is by no scientific means justified. A major change in
stent technology was seen in 2004 and 2005 when the first
promising data on Nitinol stents were reported. From our point of
view, a clinically reasonable meta-analysis should include only data
from randomized controlled trials comparing Nitinol stents vs
balloon angioplasty, that is, findings from the ABSOLUTE,3
FAST,4 and RESILIENT trials.
Martin Schillinger, MD
Erich Minar, MD
Department of Angiology
Medical University Vienna
Waehringer Guertel
Vienna, Austria
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The drawbacks of our study were addressed in the discussion
portion of our paper.
1. We were unable to acquire missing data from the authors of
included studies. The clinical heterogeneity of the included
studies was a relevant drawback because those studies were
conducted by different authors; these authors may not have
included data according to the Society for Vascular Surgery/
International Society for Cardiovascular Surgery (SVS/ISCS)
standard of reporting, thus affecting the results of the meta-
analysis.
2. A sensitivity analysis was performed that excluded studies that
might influence the final result. It did not change the findings of
our meta-analysis.
3. In the Design/Methods section of our paper, we clearly defined
re-stenosis and primary patency. Re-stenosis and patency rates
were not mixed in Table 1. Unfortunately, reporting inconsis-
tencies occurred in all studies. Some authors included restenosis
rate and others reported primary patency.
4. We agree that the issue of stent fractures cannot be reported as
an end point: We did, however, include the results of the few
studies that reported stent fractures because we have reported
our own experience in another area (carotid stenting).
5. Data for this study were collected from September 2000 and
January 2007, and Absolute and Fast were included. The
Resilient results were not available at that time. We were
amenable to the inclusion of studies that did use new stent
technology.
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Regarding “Internal endoconduit: An innovative
technique to address unfavorable iliac artery
anatomy encountered during thoracic
endovascular aortic repair”
We read with great interest the article of Peterson and Mat-
sumura1 concerning an innovative technique to deal with unfavor-
able iliac artery anatomy during thoracic endovascular aortic repair
(TEVAR). This technique allows for the safe passage of large-
profile delivery sheaths during TEVAR by means of the deploy-
ment of an iliac stent graft, followed by angioplasty and controlled
rupture of the iliac artery. We have found this technique extremely
ingenious and simple, although we agree with the authors that a
larger series needs to be examined before any conclusions can be
made about the safety of this technique.
The authors report three patients free from complications
related to decreased pelvis perfusion or iliac artery hemorrhage.
One patient had an occluded hypogastric artery, and there are no
data relating to the permeability of this artery in the remainder. We
would like to know whether the authors consider the hypogastric
artery permeability a contraindication for performing this tech-
nique; and if not, should we consider the presence of back bleeding
from the hypogastric artery after the controlled rupture of the iliac
artery an irrelevant issue?
August Ysa, MD
Maite R. Bustabad, MD
Amaia Arruabarrena, MD
Department of Vascular Surgery
Hospital de Cruces
Barakaldo, Bizkaia, Spain
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We are pleased that you are interested in our report on the
endoconduit.1 In the two subsequent cases mentioned in the case
report, the hypogastric arteries were patent, as they have been in
two out of three cases utilizing the endoconduit since submission
of the original manuscript. We understand your concern regarding
back-bleeding from a patent hypogastric artery using the endocon-
duit technique, but in our experience, the endoconduit alone
seems to prevent back-bleeding; and therefore, we do not consider
a patent hypogastric artery to be an absolute contraindication to
using an endoconduit. Similar findings have been reported in the
literature when one considers the absence of type II endoleak with
hypogastric artery orifice coverage without coil embolization
during the endovascular management of aortoiliac aneurysms.2
In our cases, the controlled ruptures have seemed to take place
in the mid-external iliac artery. However, if the area of stenosis
that mandates the use of an endoconduit is adjacent to the
hypogastric origin and rupture is anticipated in this area, a
preemptive strategy of embolizing the hypogastric main trunk
when it is patent could be useful to prevent back-bleeding. Once
again, we appreciate your interest in our article. We hope that
this technique helps you and others address unfavorable iliac
anatomy during aortic endovascular procedures, and we agree
that larger series are needed to draw definitive conclusions
regarding the safety of this technique.
Brian G. Peterson, MD
Division of Vascular Surgery
Saint Louis University
St Louis, Mo
Jon S. Matsumura, MD
Division of Vascular Surgery
Northwestern University
Chicago, Ill
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Regarding “Endovascular repair of ruptured
abdominal aortic aneurysms”
A meta-analysis by Mastracci et al1 concluded that mortality in
patients undergoing endovascular repair of ruptured abdominal
aortic aneurysms was lower than that in historical reports of un-
selected patients undergoing open repair. Only the endovascular
repair arms (representing 436 patients) of the controlled compar-
isons reported, however, were summarized in the meta-analysis
because the authors hypothesized that control groups would be
variable in their composition and that many would be clearly
biased. In a previous meta-analysis by Visser et al (representing 608
patients: 204 in the endovascular repair group and 404 in the open
repair group),2 an odds ratio (OR) for mortality adjusted for
patients’ hemodynamic condition at presentation in the hospital
was calculated by performing a meta-regression analysis in which
they included the proportion of patients with low systolic blood
pressures in each treatment group as covariate in the regression
model. In another attempt to correct for and minimize selection
bias that exists in observational studies, we herein performed a
meta-analysis pooling not crude but adjusted ORs reported in
comparative studies of endovascular vs open repair of ruptured
abdominal aortic aneurysms.
Our comprehensive search identified four (two prospective3,4
and two retrospective5,6) observational studies reporting an ad-
justed OR and only one randomized controlled trial.7 Moore et al3
used a logistic regression model including systolic blood pressure,
absence of systolic blood pressure, and glomerular filtration rate.
In the study by Peppelenbosch et al,4 the factors for which adjust-
ment was made included advanced age, male gender, hemody-
namic shock (systolic tension 100 mm Hg), and a history of
pulmonary disease. Greco et al5 used multivariate logistic regres-
sion analysis in which the dichotomous covariates included were
procedure (open or endovascular); demographic variables of
age (younger or older than 65), gender, and race; and comor-
bidities (diabetes, hypertension, emphysema, coronary, periph-
eral vascular disease, renal, cerebral, and lipids). In the study by
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